Coya Therapeutics, Inc. (COYA)Healthcare | Biotechnology | Houston, United States | NasdaqCM
4.78 USD
+0.30
(6.696%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 4.83 +0.05 (1.031%) ⇧ (April 17, 2026, 7:59 p.m. EDT) Short-term: ★★★★☆ | Long-term: ★★★☆☆ | Dividends: ★☆☆☆☆ |
Hot Take | April 18, 2026, 10:26 p.m. EDT
Coya Therapeutics is positioned as a pure momentum and near-term catalyst play with a 'strong buy' analyst streak driving upside to $15, but it lacks any dividend utility or stability. The $23M capital raise has solved immediate liquidity needs, but the stock trades below its $15.64 analyst target by roughly 70%. Options flow is overwhelmingly bullish, pinning calls at the $7.50-$10.00 range for May expiration with razor-thin implied volatility, signaling a high-conviction bet on a multi-month rally before earnings touches off a repeat of the historic 2027% revenue growth reported in previous cycles. Investors should treat this as a high-beta speculative entry, not a value hold. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.069554 |
| AutoTheta | 0.071940 |
| AutoETS | 0.072206 |
| MSTL | 0.072315 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 60% |
| H-stat | 2.04 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.088 |
| Excess Kurtosis | -0.65 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | 0.475 |
| Market Cap | 112,125,344 |
| Forward P/E | -4.14 |
| Beta | 0.52 |
| Profit Margins | -267.14% |
| Website | https://www.coyatherapeutics.com |
As of April 18, 2026, 10:26 p.m. EDT: Options flow shows pronounced bullish skew. May 15th calls exhibit heavy positioning at the $7.5 strike (Top OI) alongside strong volume at the $10.0 strike, indicating speculative bets for a 60%+ move by May. Implied volatility is extremely low (1.1-6.73%) for these near-term/mid-term expirations, suggesting speculators expect low uncertainty or a 'long gamma' move. Near-term (Apr 17) calls are active, while put volume is negligible and clustered only at deep intrinsic strikes ($2.50), with no meaningful OTM put support. The implied volatility disparity between expirations suggests a compression drive or momentum play rather than a risk-off hedge.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.16287214 |
| Address1 | 5,850 San Felipe St. |
| Address2 | Suite 500 |
| All Time High | 10.69 |
| All Time Low | 3.21 |
| Ask | 4.81 |
| Ask Size | 1 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 169,130 |
| Average Daily Volume3 Month | 154,909 |
| Average Volume | 154,909 |
| Average Volume10Days | 169,130 |
| Beta | 0.518 |
| Bid | 4.75 |
| Bid Size | 1 |
| Book Value | 2.055 |
| City | Houston |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 4.78 |
| Current Ratio | 8.505 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 4.82 |
| Day Low | 4.53 |
| Display Name | Coya Therapeutics |
| Earnings Timestamp | 1,773,664,200 |
| Earnings Timestamp End | 1,778,761,800 |
| Earnings Timestamp Start | 1,778,761,800 |
| Ebitda | -20,238,262 |
| Ebitda Margins | -2.54705 |
| Enterprise To Ebitda | -3.227 |
| Enterprise To Revenue | 8.219 |
| Enterprise Value | 65,302,548 |
| Eps Current Year | -1.64 |
| Eps Forward | -1.155 |
| Eps Trailing Twelve Months | -1.27 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 4.5387 |
| Fifty Day Average Change | 0.2413001 |
| Fifty Day Average Change Percent | 0.053165026 |
| Fifty Two Week Change Percent | -16.287214 |
| Fifty Two Week High | 7.75 |
| Fifty Two Week High Change | -2.9699998 |
| Fifty Two Week High Change Percent | -0.38322577 |
| Fifty Two Week Low | 3.71 |
| Fifty Two Week Low Change | 1.0700002 |
| Fifty Two Week Low Change Percent | 0.28840974 |
| Fifty Two Week Range | 3.71 - 7.75 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,672,324,200,000 |
| Float Shares | 17,834,965 |
| Forward Eps | -1.155 |
| Forward P E | -4.1385283 |
| Free Cashflow | -4,613,089 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 8 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | -1.1061 |
| Gross Profits | -8,788,796 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.14766 |
| Held Percent Institutions | 0.35865003 |
| Implied Shares Outstanding | 23,457,183 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,022-12-29 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary therapies to enhance the function of regulatory T cells (Tregs). Its candidate product pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. The company develops COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages in Phase 2 trial for use in the treatment of amyotrophic lateral sclerosis, as well as frontotemporal dementia, Alzheimer's disease (AD), and Parkinson's disease. In addition, its pre-clinical product candidates include COYA 301, a low-dose interleukin 2 product candidate to treat AD; COYA 303, an investigational biologic combination of COYA 301 and a glucagon-like-peptide-1 receptor agonist for the treatment of inflammatory diseases; COYA 201, an antigen directed Treg-derived exosome product candidate to treat neurodegenerative, autoimmune, and metabolic diseases; COYA 206, an antigen directed Treg-derived exosome product candidate; and COYA 101. It has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. Coya Therapeutics, Inc. was founded in 2020 and is headquartered in Houston, Texas. |
| Long Name | Coya Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 112,125,344 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_700238507 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -21,226,108 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 112,359,906 |
| Number Of Analyst Opinions | 7 |
| Open | 4.55 |
| Operating Cashflow | -10,739,301 |
| Operating Margins | -1.07507 |
| Payout Ratio | 0.0 |
| Phone | 800 587 8170 |
| Post Market Change | 0.049299717 |
| Post Market Change Percent | 1.0313748 |
| Post Market Price | 4.8293 |
| Post Market Time | 1,776,470,369 |
| Previous Close | 4.48 |
| Price Eps Current Year | -2.9146342 |
| Price Hint | 4 |
| Price To Book | 2.326034 |
| Price To Sales Trailing12 Months | 14.111356 |
| Profit Margins | -2.67138 |
| Quick Ratio | 7.974 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | 0.3 |
| Regular Market Change Percent | 6.69643 |
| Regular Market Day High | 4.82 |
| Regular Market Day Low | 4.53 |
| Regular Market Day Range | 4.53 - 4.82 |
| Regular Market Open | 4.55 |
| Regular Market Previous Close | 4.48 |
| Regular Market Price | 4.78 |
| Regular Market Time | 1,776,456,000 |
| Regular Market Volume | 219,364 |
| Return On Assets | -0.26864 |
| Return On Equity | -0.51392 |
| Revenue Growth | 2,027.688 |
| Revenue Per Share | 0.475 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 23,457,183 |
| Shares Percent Shares Out | 0.0376 |
| Shares Short | 882,759 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 843,949 |
| Short Name | Coya Therapeutics, Inc. |
| Short Percent Of Float | 0.0396 |
| Short Ratio | 6.38 |
| Source Interval | 15 |
| State | TX |
| Symbol | COYA |
| Target High Price | 18.0 |
| Target Low Price | 14.0 |
| Target Mean Price | 15.64286 |
| Target Median Price | 15.5 |
| Total Cash | 46,822,784 |
| Total Cash Per Share | 1.996 |
| Total Debt | 0 |
| Total Revenue | 7,945,753 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.27 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 5.548025 |
| Two Hundred Day Average Change | -0.7680249 |
| Two Hundred Day Average Change Percent | -0.13843213 |
| Type Disp | Equity |
| Volume | 219,364 |
| Website | https://www.coyatherapeutics.com |
| Zip | 77,057 |